倍他乐克治疗室性心律失常的疗效观察
Journal of Gannan Medical College（2005）
Abstract
心律失常抑制试验(CAST)使β受体阻滞剂成为治疗有症状的良性或可能恶性室性早搏(VPB) 的首选抗心律失常药物[1].我院应用无内源性拟交感活性心脏选择β1受体阻滞剂--倍他乐克治疗室性早搏患者54例,疗效满意,现报告如下.
MoreAI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined